Become an IMR Panelist
IMR Logo

Diabetic Kidney Disease Market - Size & Upcoming Industry Trends (2024-2032)

Diabetic Kidney Disease Market by Type (Type 1 Diabetes, Type 2 Diabetes), Treatment (Angiotensin Receptor Blockers (ARBs), Angiotensin-Converting Enzyme (ACE) Inhibitors, Antioxidant Inflammation Modulator, Calcium Channel Blockers, Others), Distribution Channel (Online Pharmacy, Hospital Pharmacy, Retail Pharmacy) and Region (North America, Eastern Europe, Western Europe, Asia Pacific, Middle East & Africa, South America)

  • Report ID : 19269
  • Category : Diagnostics
  • Format :Excel formatPDF formatWord format
Request Sample

Diabetic Kidney Disease Market Synopsis:

Diabetic Kidney Disease Market Size Was Valued at USD 2.7 Billion in 2023, and is Projected to Reach USD 4.4 Billion by 2032, Growing at a CAGR of 5.4% From 2024-2032.

Diabetic Kidney Disease (DKD), sometimes referred to as diabetic nephropathy, is a chronic kidney disease triggered by injuries to the kidneys resulting from long-term diabetes effects mostly in T1DM and T2DM patients. Another is described by the progressive worsening of the kidney functionality hinding the failure of the organ if not treated. This condition is caused by high blood sugar levels that affect blood vessels in the kidneys and reduce their capacity for clearing waste products. This is one of the main conditions leading to ESRD and patients develops dialysis or kidney transplantation.

Demand for Diabetic Kidney Disease treatment has been on the rise in recent years because of the steady upward trend of diabetes cases globally. Especially technology for diagnosis kit and immunosuppressive therapy, increasing incidences of both Type 1 and 2 diabetes which make diabetic patients more prone to chronic kidney diseases will foster the growth of this market. The International Diabetes Federation gave a figure of 537 million adults living with diabetes in 2021, and further millions are expected to develop the condition in the next few years. Admission rates for diabetic complications like diabetic kidney disease are increasing due to increasing cases of diabetes and people living with diabetes are aging.

Another factor that cannot be overlooked when reviewing the sources of the DKD market growth is the increasing knowledge of complication diagnosing and its treatment. Nuevoas diagnosticos, medicamentos y terapias emporque DKD enhanced the quality of life for the diabetic patients including AEC inhibitors, ARBs. Governments and other healthcare organizations are also dedicating a greater amount of spending on awareness campaigns regarding early diagnosis and treatment, which will provide added fuel to the fire in terms of market growth. However, factors such as the expensive cost of treatment and poor access to quality health service in the developing economies may limit the growth of the market in some markets.

Diabetic Kidney Disease Market - Size & Upcoming Industry Trends (2024-2032)

Diabetic Kidney Disease Market Trend Analysis:

Increasing Focus on Novel Therapies

  • A major trend that is revolutionizing the Diabetic Kidney Disease market pool is the use of staking on new therapeutic platform: precision medicine and biologics. The currently the medications such as ACE inhibitors and ARBs are important for treating DKD because of the newer drug class including SGLT2 inhibitors and non-steroidal MRAs. Clinical trials as well as research projects concerning the usefulness of these innovative therapies indicate that they slow the progression of DKD and decrease cardiovascular complications. Also, new approaches to a patient???s treatment tailored to his or her genotype are being developed, enhancing patient-oriented therapy and the latter???s results. The research pipeline in this area is quite deep, and many drug makers are starting to devote large sums to discovering new treatments.

Expanding Opportunities in Early Detection and Prevention

  • One of the major opportunities of the Diabetic Kidney Disease market is that there is potential to identify renal hazards at early stages among diabetic patients. Thus, there can be observed more and more attention to cost-efficient models of primary prevention and to identification of populations that are most likely to deteriorate their health in the nearest future. Point of care diagnostics, biomarker based tests and wearables are being invented to measure kidney function and blood glucose more effectively. As with most diseases, early identification of kidney dysfunction can help healthcare practitioners prevent or slow the progression of severe kidney injury. Moreover, the adoption of remote patient monitoring apps such as telemedicine enables market players to address the DKD patient population in the currently underpenetrated or rural markets that present a significant and growing opportunity.

Diabetic Kidney Disease Market Segment Analysis:

Diabetic Kidney Disease Market Segmented on the basis of type, Treatment and Distribution Channel.

By Type, Type 1 Diabetes segment is expected to dominate the market during the forecast period

  • From the type perspective, the Type 1 Diabetes segment would hold the major share in the Diabetic Kidney Disease market throughout the forecast period. Hypertension can still be associated with either type of diabetes but the patients with type 1 diabetes have higher chances of developing the disease because they have exposed their kidneys for a longer period. Diabetic complications are bound to surface at an earlier stage in Type 1 diabetes since the disease usually develops in early childhood. Chronic exposure to high blood sugar levels manifests in severe and irreversible long term effects in the kidneys. Therefore, we see a more demand for preventive therapeutic modes as well as the early stage therapies for the treatment of DKD among the type 1 diabetic patient population driving this segment.

By Treatment, Angiotensin Receptor Blockers (ARBs) segment expected to held the largest share

  • As for the treatment segment, the Angiotensin Receptor Blockers (ARBs) would dominate the Diabetic Kidney Disease market in the forecast period. ARBs are usually prescribed in the therapy of hypertension and lowering proteinuria in patients with DKD. Since angiotensin II constrains blood vessels, ARBs prevent its impact resulting to reduced blood pressure and preserving the kidney in the process. Nine were usually recommended for use in patients with DKD to halt its progression rates. This wider prescription among diabetic patients coupled with effectiveness of ARBs and low incidence of side effects than other therapies enhance their market demand. Also, growing the prescriptions of combination therapies which comprise of an ARB are also enhancing the growth of this segment.

Diabetic Kidney Disease Market Regional Insights:

North America is Expected to Dominate the Market Over the Forecast period

  • According to the report, in 2023 North America has witnessed the highest market share in the Diabetic Kidney Disease market. High incidence of diabetes, well-developed healthcare infrastructure, accessibility of advanced treatment for DKD are some of the factors which has provide dominance to this region. Especially, the U.S. has a large number of diabetes patients, 34 million people were diagnosed with the disease. Moreover, ongoing pharmaceutical innovation in the key pharmaceutical companies developing novel treatments for DKD also supports this industry and as per this leadership status will continue. The North America region is projected to account for approximately 40% of the market share for the DKD market due to the following factors: The ongoing improvement and research progress of drugs integral to the treatment of DKD general reimbursement policies in North America, and the central concentration on the early diagnosis of the DKD.

Active Key Players in the Diabetic Kidney Disease Market:

  • AbbVie Inc. (USA)
  • AstraZeneca PLC (UK)
  • Bayer AG (Germany)
  • Boehringer Ingelheim (Germany)
  • Bristol-Myers Squibb (USA)
  • Eli Lilly and Company (USA)
  • GlaxoSmithKline plc (UK)
  • Johnson & Johnson (USA)
  • Merck & Co., Inc. (USA)
  • Novartis AG (Switzerland)
  • Novo Nordisk A/S (Denmark)
  • Pfizer Inc. (USA)
  • Sanofi (France)
  • Takeda Pharmaceutical Company Ltd. (Japan)
  • Teva Pharmaceutical Industries Ltd. (Israel)
  • Other Active Players

Diabetic Kidney Disease Market

Base Year:

2023

Forecast Period:

2024-2032

Historical Data:

2017 to 2023

Market Size in 2023:

USD 2.7 Billion

Forecast Period 2024-32 CAGR:

 5.4%

Market Size in 2032:

USD 4.4 Billion

Segments Covered:

By Type
  • Type 1 Diabetes
  • Type 2 Diabetes

By Treatment
  • Angiotensin Receptor Blockers (ARBs)
  • Angiotensin-Converting Enzyme (ACE) Inhibitors
  • Antioxidant Inflammation Modulator
  • Calcium Channel Blockers
  • Others

By Distribution Channel
  • Online Pharmacy
  • Hospital Pharmacy
  • Retail Pharmacy

By Region
  • North America (U.S., Canada, Mexico)
  • Eastern Europe (Russia, Bulgaria, The Czech Republic, Hungary, Poland, Romania, Rest of Eastern Europe)
  • Western Europe (Germany, UK, France, The Netherlands, Italy, Spain, Rest of Western Europe)
  • Asia Pacific (China, India, Japan, South Korea, Malaysia, Thailand, Vietnam, The Philippines, Australia, New-Zealand, Rest of APAC)
  • Middle East & Africa (Turkiye, Bahrain, Kuwait, Saudi Arabia, Qatar, UAE, Israel, South Africa)
  • South America (Brazil, Argentina, Rest of SA)

Key Market Drivers:
  • Increasing prevalence of diabetes worldwide

Key Market Restraints:
  • High cost of DKD treatments

Key Opportunities:
  • Growing focus on early detection and prevention

Companies Covered in the report:
  • AbbVie Inc., AstraZeneca PLC, Merck & Co., Inc., Eli Lilly and Company, Sanofi and Other Active Players.

Frequently Asked Questions :

What would be the forecast period in the Diabetic Kidney Disease Market research report?

The forecast period in the Diabetic Kidney Disease Market research report is 2024-2032.

Who are the key players in the Diabetic Kidney Disease Market?

AbbVie Inc. (USA), AstraZeneca PLC (UK), Bayer AG (Germany), Boehringer Ingelheim (Germany), Bristol-Myers Squibb (USA), Eli Lilly and Company (USA), GlaxoSmithKline plc (UK), Johnson & Johnson (USA), Merck & Co., Inc. (USA), Novartis AG (Switzerland), Novo Nordisk A/S (Denmark), Pfizer Inc. (USA), Sanofi (France), Takeda Pharmaceutical Company Ltd. (Japan), Teva Pharmaceutical Industries Ltd. (Israel), and Other Active Players.

What are the segments of the Diabetic Kidney Disease Market?

The Diabetic Kidney Disease Market is segmented into Type, Treatment, Distribution Channel and region. By Type, the market is categorized into Type 1 Diabetes, Type 2 Diabetes. By Treatment, the market is categorized into Angiotensin Receptor Blockers (ARBs), Angiotensin-Converting Enzyme (ACE) Inhibitors, Antioxidant Inflammation Modulator, Calcium Channel Blockers, Others. By Distribution Channel, the market is categorized into Online Pharmacy, Hospital Pharmacy, Retail Pharmacy. By region, it is analyzed across North America (U.S., Canada, Mexico), Eastern Europe (Russia, Bulgaria, The Czech Republic, Hungary, Poland, Romania, Rest of Eastern Europe), Western Europe (Germany, UK, France, The Netherlands, Italy, Spain, Rest of Western Europe), Asia Pacific (China, India, Japan, South Korea, Malaysia, Thailand, Vietnam, The Philippines, Australia, New-Zealand, Rest of APAC), Middle East & Africa (Turkiye, Bahrain, Kuwait, Saudi Arabia, Qatar, UAE, Israel, South Africa), South America (Brazil, Argentina, Rest of SA)

What is the Diabetic Kidney Disease Market?

Diabetic Kidney Disease (DKD), sometimes referred to as diabetic nephropathy, is a chronic kidney disease triggered by injuries to the kidneys resulting from long-term diabetes effects mostly in T1DM and T2DM patients. Another is described by the progressive worsening of the kidney functionality hinding the failure of the organ if not treated. This condition is caused by high blood sugar levels that affect blood vessels in the kidneys and reduce their capacity for clearing waste products. This is one of the main conditions leading to ESRD and patients develops dialysis or kidney transplantation.

How big is the Diabetic Kidney Disease Market?

Diabetic Kidney Disease Market Size Was Valued at USD 2.7 Billion in 2023, and is Projected to Reach USD 4.4 Billion by 2032, Growing at a CAGR of 5.4% From 2024-2032.

Request Sample

Related Reports

Services Designed to Meet Your Priorities

Understand your customers' needs so can deliver better services and experiences.

Show more

Subscribe to our Newsletter

Stay in touch with us to get latest news and discount coupons.